External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<p>The US business witnessed improved traction and grew ~1% QoQ, led by market share gains in Albuterol and Arformoterol. Its respiratory pipeline in the US (Abraxane, gAdvair, and gDulera), along with gRevlimid, offers good growth visibility in the medium term. Maintain BUY. Ciplas Q2 results were largely in line with estimates as strong growth trends in India, South Africa, and EM markets were partially offset by lower gross margin (~80-100bps impact, inventory provisioning). EBITDA margin, at 22.2%, largely came in line with company guidance.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

The US business witnessed improved traction and grew ~1% QoQ, led by market share gains in Albuterol and Arformoterol. Its respiratory pipeline in the US (Abraxane, gAdvair, and gDulera), along with gRevlimid, offers good growth visibility in the medium term. Maintain BUY. Ciplas Q2 results were largely in line with estimates as strong growth trends in India, South Africa, and EM markets were partially offset by lower gross margin (~80-100bps impact, inventory provisioning). EBITDA margin, at 22.2%, largely came in line with company guidance.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cipla (Results Review 2QFY22): In-line quarter; upbeat on outlook. Maintain BUY

Cipla Ltd

Cipla (Results Review 2QFY22): In-line quarter; upbeat on outlook. Maintain BUY